Table 1. Demographics according to 18F-FAMT uptake.
| Variables | High 18F-FAMT (n=20) | Low 18F-FAMT (n=22) | P-value |
|---|---|---|---|
| Age (years, ⩽65/>65) |
11/9 |
10/12 |
0.75 |
| Sex, M/F |
18/2 |
19/3 |
>0.999 |
| Tumour size (mm, ⩽50/>50) |
8/12 |
13/9 |
0.354 |
| Differentiation, WD-MD/PD |
14/6 |
17/5 |
0.729 |
| Lymph meta, yes/no |
16/4 |
10/12 |
0.028 |
| Staging, I+II/III+IV |
6/14 |
18/4 |
0.001 |
| Lymphatic invasion, yes/no |
18/2 |
15/7 |
0.134 |
| Vascular invasion, yes/no |
17/3 |
13/9 |
0.091 |
|
LAT1 | |||
| High/low | 17/3 | 1/21 | <0.001 |
| Positive/negative |
20/0 |
16/6 |
0.022 |
|
CD98 | |||
| High/low | 18/2 | 4/18 | <0.001 |
| Positive/negative |
20/0 |
14/8 |
0.004 |
| Glut1, Score 4–5/1–3 |
18/2 |
11/11 |
0.007 |
| Ki-67, high/low |
15/5 |
6/16 |
<0.001 |
| CD34, high/low |
13/7 |
5/17 |
<0.001 |
| EGFR, high/low |
15/5 |
15/7 |
0.738 |
| p-Akt, high/low |
6/14 |
9/13 |
0.531 |
| p-mTOR, high/low |
2/18 |
7/15 |
0.134 |
| p53, positive/negative | 14/6 | 16/6 | >0.999 |
Abbreviations: EGFR=epidermal growth receptor factor; 18F-FAMT=L-[3-18F]-α–methyltyrosine; Glut1=glucose transporter 1; LAT1=L-type amino acid transporter 1; M/F=male/female; p-mTOR=phospho-mammalian targeting of rapamycin. The bold entries show statistically significant difference.